1. Home
  2. CHA vs GH Comparison

CHA vs GH Comparison

Compare CHA & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHA
  • GH
  • Stock Information
  • Founded
  • CHA 2017
  • GH 2011
  • Country
  • CHA China
  • GH United States
  • Employees
  • CHA N/A
  • GH N/A
  • Industry
  • CHA
  • GH Medical Specialities
  • Sector
  • CHA
  • GH Health Care
  • Exchange
  • CHA NYSE
  • GH Nasdaq
  • Market Cap
  • CHA 5.5B
  • GH 4.9B
  • IPO Year
  • CHA 2025
  • GH 2018
  • Fundamental
  • Price
  • CHA $28.01
  • GH $40.62
  • Analyst Decision
  • CHA
  • GH Strong Buy
  • Analyst Count
  • CHA 0
  • GH 21
  • Target Price
  • CHA N/A
  • GH $52.81
  • AVG Volume (30 Days)
  • CHA 1.1M
  • GH 2.3M
  • Earning Date
  • CHA 05-30-2025
  • GH 04-30-2025
  • Dividend Yield
  • CHA N/A
  • GH N/A
  • EPS Growth
  • CHA 186.29
  • GH N/A
  • EPS
  • CHA 1.95
  • GH N/A
  • Revenue
  • CHA $1,699,604,333.00
  • GH $773,996,000.00
  • Revenue This Year
  • CHA N/A
  • GH $23.05
  • Revenue Next Year
  • CHA N/A
  • GH $21.40
  • P/E Ratio
  • CHA $14.34
  • GH N/A
  • Revenue Growth
  • CHA 167.35
  • GH 28.20
  • 52 Week Low
  • CHA $27.21
  • GH $20.14
  • 52 Week High
  • CHA $41.80
  • GH $52.92
  • Technical
  • Relative Strength Index (RSI)
  • CHA N/A
  • GH 48.45
  • Support Level
  • CHA N/A
  • GH $37.73
  • Resistance Level
  • CHA N/A
  • GH $39.63
  • Average True Range (ATR)
  • CHA 0.00
  • GH 1.60
  • MACD
  • CHA 0.00
  • GH -0.01
  • Stochastic Oscillator
  • CHA 0.00
  • GH 60.00

About CHA CHAGEE HOLDINGS LTD SPON ADS EACH R SPON ADS EACH REP 1 CL A

Chagee Holdings Ltd is a premium tea drinks brand. It is engaged in the sales of freshly-made tea drinks, related raw materials, packaging, teahouse equipment and other supplies in China.

About GH Guardant Health Inc.

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: